Latest News

Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.
Lung Cancer Screening Adherence Decreases Across Subsequent Testing

April 24th 2025

Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.
Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

April 23rd 2025

“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).
TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer

April 23rd 2025

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC
Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

April 23rd 2025

3 Things You Should Know About Unresectable NSCLC
3 Things You Should Know About Unresectable NSCLC

April 21st 2025